Latest Breaking News On - Marcp bonaca - Page 1 : comparemela.com

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

The study may raise more questions than it answers, particularly around the idea of what constitutes “vulnerable.”

Soult ukpyolsiSouth koreaStoke on trentUnited kingdomCity ofUnited statesRepublic of koreaRasha al lameeMarcp bonacaAmerican college of cardiologyDphil keele universityPhd imperial college londonMd brown universityMd university of colorado school medicineSeung jung parkMasan medical

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

Low bleeding liability with the XIa inhibitor may mean higher doses are possible, boosting efficacy, one investigator suggested.

United statesFelicita andreottiJohnw eikelboomMarcp bonacaBristol myers squibbJournal of the american college cardiologyMsc population health research instituteUniversity of colorado school medicineColorado schoolAmerican collegePopulation health research instituteFondazione policlinico universitario

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

While the field awaits targeted therapies, estimates of absolute 10-year risks can be used to counsel patients, researchers say.

United statesPetere thomasMarcp bonacaMarc bonacaEli lillyJoshuaa beckmanPiar kamstrupAlexandere sullivanMd vanderbilt university medical centerCopenhagen university hospitalUniversity of colorado school medicineJournal of the american college cardiologyMd ut southwestern medical centerAmerican college of cardiology vascular disease councilNovartis ionis pharmaceuticalsMd university of copenhagen

Marc Bonaca, MD, MPH: Benefit of Rivaroxaban for High-Risk Patients with PAD

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

United statesMarcp bonacaAmerican heart association scientific sessionsAmerican heart associationUniversity of colorado anschutz medical campusScientific sessionsColorado anschutz medical campusLow dose rivaroxaban plus aspirinMyocardial infarctionPeripheral artery disease withWithout concomitant coronary artery diseaseTotal vascular eventsFragile patientsPeripheral artery disease

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMarcp bonacaMarc bonacaJanssen scientific affairsJanssen pharmaceuticals incExchange commissionDrug administrationJanssenus janssen scientific affairsDivision of cardiovascular medicineNone of janssen scientific affairsDepartment of medicineCompanies of johnsonJanssen pharmaceutical companies of johnsonAmerican heart associationUniversity of colorado anschutz medical campusJanssen pharmaceutical companies